FDA approves NDA to determine safety, efficacy of psilocybin for OCD treatment
Click Here to Manage Email Alerts
The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.
“With positive preliminary results from a Ceruvia-funded pilot phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD,” Ceruvia CEO Carey Turnbull said in a company press release. “With few effective treatment options available for the almost 4 million Americans who suffer from OCD, our phase 2 clinical trial is an important step in helping these patients dramatically improve the quality of their lives.”
The clinical trial will be a multicenter, randomized, double-blind, active placebo-controlled trial that will examine the safety and efficacy of synthetic psilocybin for the treatment of OCD symptoms.
The company said 105 participants will receive either 25 mg of SYNP-101 (synthetic psilocybin) or active placebo. The primary endpoint of the trial is to determine the reduction of OCD symptoms for up to 12 weeks after a single dose of SYNP-101.
The trial will begin in the second half of 2022, the company said in the release.